Answers are grounded in this paper and cite their sources.
18 F-PSMA-1007 PET/CT is widely used for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) for 177Lu-PSMA radioligand therapy. We present a striking case in which multiple skeletal metastases demonstrated intense, reproducible ¹⁷⁷Lu-PSMA-617 uptake on post-therapy scintigraphy across all three treatment cycles, yet remained occult or only minimally avid on serial ¹⁸F-PSMA-1007 PET/CT. SPECT/CT confirmed anatomic lesion localization, excluding artifact. This case of “reverse theranostic discordance” challenges the assumption that diagnostic PSMA PET faithfully represents the full target landscape for radioligand therapy. Systematic SPECT/CT review after treatment cycles may reveal therapeutically relevant disease invisible to pretherapy PET.
No takes yet. Share an insight, caveat, or question.
Mahdi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: